Compass Therapeutics reports phase 1 data for CTX-8371 at ASCO meeting

May 21, 2026 5:00 PM

Compass Therapeutics Inc. (NASDAQ: CMPX) announced it will present phase 1 clinical data for CTX-8371 at the 2026 American Society ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found